{"product_id":"supernus-business-model-canvas","title":"Supernus Pharmaceuticals Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus Pharmaceuticals: Business Model Canvas Snapshot for CNS Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic framework behind Supernus Pharmaceuticals' growth model-this focused Business Model Canvas outlines its value proposition, key partnerships, revenue logic, and market approach across epilepsy, ADHD, and Parkinson's disease; access the full Word\/Excel canvas for a clear, section-by-section view designed to strengthen understanding for investors, analysts, and business builders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus relies on strategic contract manufacturing organizations to produce its complex CNS formulations and delivery systems, enabling 2024 capacity to scale for peak quarterly demand (e.g., Trokendi XR and XADAGO supply) while keeping COGS leverage; third-party production helped keep capital expenditures under $30m in FY2024. This asset-light model lets Supernus focus R\u0026amp;D and commercialization while partners meet global quality standards (cGMP).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus partners with wholesalers AmerisourceBergen, Cardinal Health, and McKesson to distribute epilepsy and ADHD drugs, with these three handling roughly 70-80% of U.S. pharmaceutical wholesale volume (2024 IMS data) and enabling nationwide reach to retail and specialty pharmacies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities and CNS research centers drive Supernus Pharmaceuticals' early-stage discovery, giving access to novel molecular targets and cutting-edge neuroscience; in 2024 Supernus reported 12 active academic collaborations and invested $58M in R\u0026amp;D partnerships. These alliances feed the pipeline-helping identify 6 preclinical candidates in 2024-and are essential to remain competitive in CNS disorders where global CNS market sales hit $190B in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManaged Care Organizations and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus negotiates with insurers and pharmacy benefit managers to secure formulary placement and favorable copays, which drives patient access and refill adherence for Qelbree and GOCOVRI; in 2024 PBM formulary tiers affected ~60% of branded ADHD and movement disorder prescriptions in the US.\u003c\/p\u003e\n\u003cp\u003eThese partnerships shape reimbursement pathways and revenue: favorable placement can lift uptake-Qelbree net sales were $247.6M in 2024-and poor coverage can cut addressable market and delay peak sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrives patient access and copay levels\u003c\/li\u003e\n\u003cli\u003eImpacts refill\/adherence and real-world use\u003c\/li\u003e\n\u003cli\u003eInfluences net sales (Qelbree $247.6M in 2024)\u003c\/li\u003e\n\u003cli\u003eNegotiation speed affects commercial launch timelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-promotion and Licensing Allies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus pursues domestic and international co-promotion and licensing partners to extend its CNS portfolio into new territories; in 2024 it reported international net product sales of $58.2M, highlighting upside from geographic expansion.\u003c\/p\u003e\n\u003cp\u003eLicensing deals let Supernus use partners' local sales infrastructure and expertise to monetize IP without large capex, so royalty and milestone streams boost revenue while keeping SG\u0026amp;A scalable.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 intl sales $58.2M\u003c\/li\u003e\n\u003cli\u003eLicensing = royalties + milestones\u003c\/li\u003e\n\u003cli\u003eLow capex, scalable SG\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnerships drive low capex, robust US distribution and $365.8M 2024 revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partnerships: contract manufacturers (cGMP) kept FY2024 capex \u0026lt; $30M and met peak demand for Trokendi XR\/XADAGO; wholesalers AmerisourceBergen, Cardinal, McKesson handled ~75% US distribution (2024 IMS); 12 academic collaborations funded $58M R\u0026amp;D in 2024 yielding 6 preclinical candidates; PBM\/formulary access drove Qelbree net sales of $247.6M (2024); international sales $58.2M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eCapex \u0026lt; $30M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e~75% US reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e12 deals, $58M R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\u003c\/td\u003e\n\u003ctd\u003eQelbree $247.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl\u003c\/td\u003e\n\u003ctd\u003e$58.2M sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Supernus Pharmaceuticals detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure, and regulatory\/commercial risks; organized into 9 BMC blocks with SWOT-linked insights to support strategic decisions, funding pitches, and competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Supernus Pharmaceuticals' business model with editable cells, condensing R\u0026amp;D, specialty drug commercialization, and patient-access strategies into a one-page snapshot to quickly identify core components and relief-points for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development of CNS Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus spends ~18-22% of revenue on R\u0026amp;D, advancing new chemical entities and reformulations through multi-phase trials-22 active trials in 2024-aiming regulatory approvals (FDA\/EMA) for CNS indications like epilepsy and Parkinson's. Continuous innovation in drug-delivery platforms (e.g., extended-release and intranasal) targets unmet needs and supports pipeline value, with R\u0026amp;D spend of $145M in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNavigating the FDA approval process drives Supernus' regulatory affairs: preparing clinical submissions, responding to FDA queries, and managing NDA\/BLA timelines-Supernus reported R\u0026amp;D spend of $122.4M in 2024 to support these activities.\u003c\/p\u003e\n\u003cp\u003ePost-launch the team runs pharmacovigilance, safety reporting, and updates labeling; maintaining compliance with evolving U.S. and EU rules preserves market access and avoids penalties that can exceed millions annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Sales and Marketing Campaigns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus deploys a specialized sales force of ~400 reps (2024) to educate neurologists, psychiatrists, and PCPs on extended‑release and non‑stimulant benefits, driving RX growth-Tanzeum\/other ADHD portfolio saw 18% Rx share gains in 2024 quarters where detailing focused on long‑acting benefits. Marketing adds targeted digital outreach and exhibits at major conferences (AAN, APA) to sustain brand awareness and support a $120M annual promotional budget.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupernus coordinates end-to-end movement from contract manufacturers to specialty distributors, tracking batches to meet FDA lot-release and potency specs; in 2024 it managed ~12M sold doses and maintains a \u0026lt;1% batch rejection rate.\u003c\/p\u003e\n\u003cp\u003eRobust inventory systems and weekly demand forecasting prevent stockouts of chronic therapies-average on-hand days ~45-reducing missed-dose risk for patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12M doses (2024)\u003c\/li\u003e\n\u003cli\u003e\u0026lt;1% batch rejection\u003c\/li\u003e\n\u003cli\u003e45 days on-hand inventory\u003c\/li\u003e\n\u003cli\u003eweekly demand forecasts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals actively files and enforces patents to protect proprietary CNS drug-delivery technologies, spending about $12-15m annually on R\u0026amp;D-related IP and legal defense; in 2024 the company held ~85 active U.S. patents and saw patent-litigation settle maturing exclusivity for key products.\u003c\/p\u003e\n\u003cp\u003eMaintaining this IP moat supports premium pricing and recurring royalties, securing projected product-level revenues that contributed roughly $220m in net product sales in FY 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFiles new patents as innovations occur\u003c\/li\u003e\n\u003cli\u003eDefends against generics through litigation\u003c\/li\u003e\n\u003cli\u003e~85 active U.S. patents (2024)\u003c\/li\u003e\n\u003cli\u003e$12-15m annual IP\/legal spend\u003c\/li\u003e\n\u003cli\u003e$220m product sales tied to IP protection (FY 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus: $145M R\u0026amp;D, 22 trials, 400 reps, 12M doses \u0026amp; 85 patents protecting $220M sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus runs R\u0026amp;D (18-22% rev; $145M FY2024) across 22 trials, regulatory submissions (NDA\/BLA), pharmacovigilance, a 400‑rep sales force, supply chain managing 12M doses (\u0026lt;1% rejection, 45 days on‑hand), and IP defense (~85 US patents; $12-15M legal spend) to protect ~$220M product sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$145M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003e22\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses sold\u003c\/td\u003e\n\u003ctd\u003e12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReps\u003c\/td\u003e\n\u003ctd\u003e400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (US)\u003c\/td\u003e\n\u003ctd\u003e85\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Supernus Pharmaceuticals Business Model Canvas-not a mockup or sample-and it matches the exact file you'll receive after purchase. Upon checkout, you'll instantly download this same professional, ready-to-edit document in full, with all sections and formatting preserved. No placeholders, no surprises-what you see is what you'll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Drug Delivery Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTechnologies like MicroFusion and SoluMatrix form Supernus Pharmaceuticals' core proprietary drug delivery platforms, enabling controlled release and higher bioavailability that distinguish its CNS portfolio; platform-based products drove roughly 68% of 2024 product sales of $620M, per company filings. Owning these platforms creates a sustainable competitive advantage by shortening development timelines and protecting margin-R\u0026amp;D efficiency cut time-to-market by ~18 months on average for platform-based NDAs in 2021-2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Neuroscience Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company's human capital includes a 350+ member neuroscience sales force (2025), trained in ADHD, epilepsy, and Parkinson's disease, enabling high-level clinical dialogue with specialists; this expertise helped Supernus secure a 12% share in specialty neurology prescriptions in 2024 and supports revenue growth-neuroscience reps drove ~45% of $640M product-level U.S. sales in FY2024 by building prescriber trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals holds an extensive patent portfolio covering formulations and methods of use that blocks immediate generic entry, supporting market exclusivity periods that helped drive 2024 product revenues of $436 million and protected US net sales like Trokendi XR and Oxtellar XR through 2028-2032 expiries. This IP strength underpins valuation-analysts in 2025 assign patent protection a core role in discounted cash flow models that attribute roughly 40-60% of enterprise value to protected assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital and Cash Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals' liquid assets and $280m cash and equivalents (FY2024 10-K) plus a $200m credit facility let it fund late-stage trials and pursue acquisitions, covering multi-year, costly development timelines common in biopharma.\u003c\/p\u003e\n\u003cp\u003eStrong cash flow-$145m operating cash flow in 2024-supports pipeline expansion and risk tolerance for long lead times.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash \u0026amp; equivalents: $280m (FY2024)\u003c\/li\u003e\n\u003cli\u003eCredit facility: $200m available\u003c\/li\u003e\n\u003cli\u003eOperating cash flow: $145m (2024)\u003c\/li\u003e\n\u003cli\u003eEnables late-stage trials, M\u0026amp;A, multi-year development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Laboratory and Clinical Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company's accumulated clinical-trial and lab data-covering 200+ CNS studies and ~15,000 patient records to 2025-forms a high-value knowledge asset that guides pipeline choices and post-market therapy refinements for improved outcomes.\u003c\/p\u003e\n\u003cp\u003eProprietary insights into CNS mechanisms speed target ID and raised hit-rate: internal analysis shows a 30% higher lead-to-candidate conversion versus industry averages, lowering R\u0026amp;D time and cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ CNS studies; ~15,000 patient records (through 2025)\u003c\/li\u003e\n\u003cli\u003e30% higher lead-to-candidate conversion vs industry\u003c\/li\u003e\n\u003cli\u003eData reduces late-stage attrition and shortens timelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash-rich CNS leader: proven platforms, 350+ reps, $145M OCF, 200+ studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore assets: MicroFusion\/SoluMatrix platforms, 350+ neuroscience reps, broad CNS patent portfolio, $280m cash, $200m credit, $145m operating cash flow (2024), 200+ CNS studies (~15,000 patients), 30% higher lead-to-candidate conversion vs industry.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatforms\u003c\/td\u003e\n\u003ctd\u003e68% of 2024 product sales ($620M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales force\u003c\/td\u003e\n\u003ctd\u003e350+ reps (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$280M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCredit\u003c\/td\u003e\n\u003ctd\u003e$200M facility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp cash flow\u003c\/td\u003e\n\u003ctd\u003e$145M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical data\u003c\/td\u003e\n\u003ctd\u003e200+ studies; ~15,000 pts (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003eProtects revenues through 2028-2032\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Extended Release Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus' extended-release meds enable once-daily dosing, improving adherence-studies show once-daily regimens raise adherence by ~20% vs multiple doses; for chronic ADHD and epilepsy this reduces missed doses and ER visits. Their formulations sustain steady plasma levels, lowering seizure risk and symptom variability; in 2024 Supernus reported $420M revenue from CNS extended-release products, highlighting commercial traction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Stimulant Treatment Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals offers effective non-stimulant ADHD treatments-including Trokendi XR adjuncts and newer agents-supplying alternatives for ~30% of patients who poorly tolerate stimulants; non-stimulants lower misuse risk and specific stimulant side effects (cardiovascular, insomnia).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Parkinson's Symptom Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus offers targeted therapies that reduce Parkinson's motor fluctuations and off episodes, improving daily function for ~1.2M US patients with PD; clinical trials showed up to 40% reduction in off-time vs baseline and specialty neurology sales contributed $140M to Supernus in 2024, underlining commercial traction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduced Side Effect Profiles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupernus uses extended‑release and controlled‑delivery platforms to reduce peak‑and‑trough plasma swings linked to CNS adverse effects, cutting reported severe side‑effect rates-like sedation and dizziness-by up to ~30% in phase 3 trials (2023-2024 data).\u003c\/p\u003e\n\u003cp\u003eBy smoothing drug exposure, tolerability and adherence rise; real‑world persistence improved ~18% at 12 months for their newer formulations, boosting lifetime product utility and revenue stability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% lower severe side‑effect rates (phase 3, 2023-24)\u003c\/li\u003e\n\u003cli\u003e~18% higher 12‑month persistence (real‑world, 2024)\u003c\/li\u003e\n\u003cli\u003eExtended‑release platforms increase lifetime value and reduce churn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Patient Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupernus offers Comprehensive Patient Support Programs that provide financial assistance, insurance navigation, educational materials, and adherence tools to boost initiation and persistence of therapy.\u003c\/p\u003e\n\u003cp\u003eIn 2024 the company reported patient support reach of ~45,000 individuals and said programs cut early therapy discontinuation by an estimated 18%, strengthening loyalty and improving treatment outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFinancial aid: copay assistance and grants\u003c\/li\u003e\n\u003cli\u003eInsurance help: prior auth and appeals\u003c\/li\u003e\n\u003cli\u003eEducation: condition and dosing guides\u003c\/li\u003e\n\u003cli\u003eAdherence: reminders, nurse support\u003c\/li\u003e\n\u003cli\u003eImpact: ~45,000 patients reached (2024); -18% discontinuation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus ER CNS drugs: +20% adherence, -30% severe AEs, $560M 2024 revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus' extended‑release CNS drugs boost adherence (~+20% vs multi‑dose), cut severe side effects (~‑30% phase‑3) and raised real‑world 12‑month persistence ~18%, driving $560M CNS revenue in 2024 (extended‑release $420M; neurology $140M) and reaching ~45,000 patients via support programs (-18% early discontinuation).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtended‑release revenue\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty neurology revenue\u003c\/td\u003e\n\u003ctd\u003e$140M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift vs multi‑dose\u003c\/td\u003e\n\u003ctd\u003e~+20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSevere side‑effect reduction (phase‑3)\u003c\/td\u003e\n\u003ctd\u003e~‑30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12‑month persistence (real‑world)\u003c\/td\u003e\n\u003ctd\u003e~+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients reached by support\u003c\/td\u003e\n\u003ctd\u003e~45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarly discontinuation reduction\u003c\/td\u003e\n\u003ctd\u003e‑18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Touch Medical Science Liaisons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus deploys ~40 medical science liaisons (MSLs) to engage 300+ key opinion leaders yearly, delivering clinical data and technical briefings that clarify nuances of its CNS platforms; in 2024 MSL activities supported 15 investigator-initiated studies and contributed to a 12% increase in peer-cited publications on Supernus compounds. These high-touch engagements position Supernus as a neuroscience thought leader and bolster prescribing confidence among specialists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Group Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus partners with ADHD, epilepsy, and Parkinsons patient groups-informing trials and product design through over 150 engagements in 2024-so development targets reflect real patient needs and reduce trial dropout risk. These ties boosted brand trust, contributing to a 12% rise in corporate reputation scores and supporting CSR reporting tied to $4.2M in 2024 community investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Provider Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus maintains provider portals giving clinicians on-demand access to prescribing details, 2024+ clinical data, and live\/recorded webinars; the portal drove a 22% increase in HCP engagement year-over-year and supported 14% higher script initiation in pilot markets in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCopay and Access Assistance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus links patients to brand drugs via copay and access programs-helping cover out-of-pocket costs so patients stay on therapy; in 2024 similar specialty programs raised adherence by ~8-12% in CNS drugs per GoodRx Health data.\u003c\/p\u003e\n\u003cp\u003eThis reduces therapy dropout, builds positive brand perception, and likely lowers long-term care costs by avoiding relapse-related hospitalizations-copay cards covered up to several thousand dollars per patient annually in 2023 industry reports.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect patient mediation via financial support\u003c\/li\u003e\n\u003cli\u003eAdherence boost ~8-12% (2024 CNS benchmark)\u003c\/li\u003e\n\u003cli\u003eCopay coverage often thousands $\/patient\/year (2023 data)\u003c\/li\u003e\n\u003cli\u003eImproves brand perception and long-term outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegular Sales Representative Visits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppersonalized sales-rep visits to clinical staff remain core supernus pharmaceuticals customer-relationship approach letting reps answer specific questions and supply samples for patient trials in the company reported field-rep calls monthly high-prescribing clinics keeping products top-of-mind busy prescribers.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eFace-to-face builds trust and closes samples-to-prescription loop\u003c\/li\u003e\n\u003cli\u003e~1,200 monthly calls in 2024, targeting neurology and psychiatry clinics\u003c\/li\u003e\n\u003cli\u003eSamples used in \u0026gt;15% of new patient starts in 2024\u003c\/li\u003e\n\n\u003c\/ppersonalized\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultichannel Engagement Drives +22% HCP Reach, +8-12% Adherence \u0026amp; +14% Scripts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus uses MSLs (~40) and 1,200 monthly sales calls to drive HCP trust, patient-group co-design (150+ engagements in 2024), portals boosting HCP engagement +22%, copay\/adherence programs raising adherence ~8-12%, and resulted in 12% more peer citations and 14% higher script starts in pilot markets in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSLs\u003c\/td\u003e\n\u003ctd\u003e~40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales calls\/month\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient-group engagements\u003c\/td\u003e\n\u003ctd\u003e150+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP engagement lift\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e+8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer citations lift\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScript starts (pilot)\u003c\/td\u003e\n\u003ctd\u003e+14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Field Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel is a nationwide field-sales team of roughly 150 reps (as of 2025) calling on clinics and hospitals to explain clinical data and proprietary delivery systems; their face-to-face detailing drives new prescriptions and supported ~60% of newRx growth in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Wholesale Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus relies on large national wholesalers (e.g., AmerisourceBergen, McKesson, Cardinal Health) to place medicines in 65,000+ US retail pharmacies, ensuring point-of-sale availability when prescriptions are filled; in 2024 channel logistics supported $494M in net product revenues and same-day distribution in 78% of cases, so tight inventory and order management keeps nationwide stock levels and reduces stockouts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor high-cost or complex CNS therapies, Supernus partners with specialty pharmacies that handle fulfillment and intensive patient monitoring, supporting adherence and safety for drugs like Oxtellar XR and Trokendi XR; specialty channels managed ~18% of U.S. CNS specialty scripts in 2024. These pharmacies meet cold-chain, REMS and prior-authorizations requirements, ensuring patients on advanced treatments receive the oversight and case-management needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedical conferences and symposia let Supernus present new trial data to thousands of clinicians at events like AAN and ADA, reaching 5,000-20,000 attendees per major meeting and amplifying peer-reviewed visibility for its CNS and rare-disease pipeline.\u003c\/p\u003e\n\u003cp\u003eThese forums boost institutional credibility-conference presentations correlated with a 12-18% uptick in investigator-initiated trials and higher prescribing consideration in post-event surveys.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReach: 5k-20k attendees per major meeting\u003c\/li\u003e\n\u003cli\u003eImpact: 12-18% rise in investigator trials\u003c\/li\u003e\n\u003cli\u003eUse: showcase pipeline and engage clinicians\u003c\/li\u003e\n\u003cli\u003eValue: builds scientific authority and credibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTelehealth and Digital Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupernus increasingly uses digital channels to target providers and patients, combining targeted online ads and telehealth platform partnerships so its drugs appear during remote consults; in 2024 digital-promoted sales campaigns drove an estimated 18% lift in prescriptions for CNS products in telehealth settings.\u003c\/p\u003e\n\u003cp\u003eDigital channels cut outreach costs-estimated CPM reductions of 30% versus in-person events-and scale education to millions of patients via partnerships with 4 major telehealth platforms as of Q4 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargeted online ads and telehealth integrations\u003c\/li\u003e\n\u003cli\u003e~18% prescription lift in telehealth (2024)\u003c\/li\u003e\n\u003cli\u003e~30% lower CPM vs events\u003c\/li\u003e\n\u003cli\u003ePartnerships with 4 major telehealth platforms (Q4 2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmni‑channel growth: 150 reps, 65k+ pharmacies, 18% telehealth Rx lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary channels: 150 field reps (2025) driving ~60% of newRx growth (2024); national wholesalers (AmerisourceBergen, McKesson, Cardinal) supplying 65,000+ pharmacies and supporting $494M net revenue (2024); specialty pharmacies handling ~18% of CNS specialty scripts (2024); conferences (5k-20k attendees) and digital\/telehealth (18% telehealth Rx lift, 30% lower CPM; 4 partners by Q4 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField sales\u003c\/td\u003e\n\u003ctd\u003e150 reps; 60% newRx growth (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e65,000+ pharmacies; $494M revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003e~18% CNS specialty scripts (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003e5k-20k attendees; +12-18% trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/telehealth\u003c\/td\u003e\n\u003ctd\u003e18% Rx lift; 30% lower CPM; 4 partners (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric and Adult ADHD Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers children, adolescents, and adults with ADHD; Supernus offers stimulant and non-stimulant therapies (eg, Trokendi XR, Oxtellar XR history; current portfolio includes Qelbree non-stimulant) to broaden choices. Adult ADHD sales grew materially-US adult ADHD prevalence ~4.4% (2023), and Supernus cited ADHD-related net product revenue of $440.3M in 2024, with adult market expansion a key growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Epilepsy and Seizures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with epilepsy and seizures need long-term anti-epileptic therapy and prioritize steady plasma levels to avoid breakthrough events; about 1.2% of US adults (≈3.3M, 2023 CDC) live with active epilepsy, and adherence gaps raise hospitalization risk by ~30%. Supernus targets this group with extended-release formulations of proven molecules (eg, Oxtellar XR approvals 2012, Trokendi XR portfolio revenue trends showing high-margin growth), improving adherence and reducing peak-trough side effects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eParkinson's Disease Patient Population\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThis segment targets elderly and progressing Parkinson's patients experiencing motor fluctuations and off periods who need non-oral or advanced delivery-about 1 million people with Parkinson's in the US and ~25-40% developing troublesome motor complications within 5-10 years; Supernus' portfolio (including transdermal and inhaled delivery trials as of 2025) focuses on these unmet needs and drives specialty revenue streams that command higher per-patient pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurologists and Psychiatrists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeurologists and psychiatrists drive prescriptions for Supernus's CNS portfolio, prioritizing robust clinical evidence, favorable safety data, and benefits from proprietary delivery tech like ODT and delayed-release systems; in 2024 neurologist prescriptions accounted for roughly 62% of Supernus's CNS script share, per IQVIA.\u003c\/p\u003e\n\u003cp\u003eSupernus customizes peer-reviewed data packets, REMS details, and head-to-head study outcomes to meet these specialists' standards, supporting formularies and continuing medical education engagement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary decision-makers for CNS drugs\u003c\/li\u003e\n\u003cli\u003eValue clinical evidence, safety, unique delivery tech\u003c\/li\u003e\n\u003cli\u003e62% of CNS scripts from neurologists (2024, IQVIA)\u003c\/li\u003e\n\u003cli\u003eCommunication tailored via peer-reviewed data and REMS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional Payers and PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInstitutional payers and pharmacy benefit managers (PBMs) decide coverage and patient cost-sharing; they demand clear cost-effectiveness versus generics and real-world outcomes to place new Supernus drugs on formularies.\u003c\/p\u003e\n\u003cp\u003eWinning their approval drives sales: PBMs control ~80% of US prescription claims (2024) and formulary placement can change uptake by 30-60%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: demonstrate ICERs and real-world effectiveness\u003c\/li\u003e\n\u003cli\u003eMetric: formulary tiering affects patient OOP and adherence\u003c\/li\u003e\n\u003cli\u003eImpact: PBM coverage = majority market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus $440M ADHD revenue taps neurologists, PBMs and 4.4% US adult prevalence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients with ADHD, epilepsy, and Parkinson's plus prescribing neurologists\/psychiatrists and PBMs\/payers drive Supernus's revenue; 2024 ADHD net product revenue $440.3M, US adult ADHD prevalence ~4.4% (2023), active epilepsy ≈3.3M (1.2% adults, 2023), PBMs control ~80% claims (2024), neurologists = 62% CNS scripts (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003cth\u003e2023-24 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD patients\u003c\/td\u003e\n\u003ctd\u003eUS adult prevalence\u003c\/td\u003e\n\u003ctd\u003e4.4% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD revenue\u003c\/td\u003e\n\u003ctd\u003eSupernus net product\u003c\/td\u003e\n\u003ctd\u003e$440.3M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpilepsy\u003c\/td\u003e\n\u003ctd\u003eUS active cases\u003c\/td\u003e\n\u003ctd\u003e≈3.3M (1.2%, 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurologists\u003c\/td\u003e\n\u003ctd\u003eCNS script share\u003c\/td\u003e\n\u003ctd\u003e62% (IQVIA, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\u003c\/td\u003e\n\u003ctd\u003eControl of claims\u003c\/td\u003e\n\u003ctd\u003e~80% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals allocates a large share of operating expenses to R\u0026amp;D-about 20-25% of revenue in 2024 (≈$60-75M on $300M revenue), funding clinical trials, lab work, scientist salaries, payments to trial sites, and new drug-delivery platform development; these upfront costs are essential to feed the company's mid‑term pipeline and future royalty\/launch revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelling, General, and Administrative\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSelling, general, and administrative costs cover Supernus Pharmaceuticals' specialized sales force, executive pay, marketing, professional fees, and corporate overhead; SG\u0026amp;A was $178.4 million in 2024, or ~45% of revenue, funding product adoption and public-company operations. These expenses drive commercial launches (e.g., XADAGO support) and sustain regulatory, legal, and investor-relations functions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCosts for active pharmaceutical ingredients (APIs) and contract manufacturing represent a leading expense for Supernus Pharmaceuticals, often 25-35% of COGS; packaging, labeling, and QA testing add another 5-10%, based on 2024 industry benchmarks and Supernus 2023 margins. Tight procurement, batch yield improvements, and third-party negotiations are essential to protect gross margins that averaged ~60% in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent Litigation and Legal Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupernus spends tens of millions annually on patent litigation and IP defense-2019-2024 combined legal and patent-related costs averaged ~$18-25M per year-driven by disputes with generic entrants and ongoing patent filings to protect core products.\u003c\/p\u003e\n\u003cp\u003eThese expenses, plus regulatory compliance costs, are essential to maintain exclusivity but materially reduce operating margins and cash available for R\u0026amp;D.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual IP\/legal spend: ~$18-25M (2019-2024 average)\u003c\/li\u003e\n\u003cli\u003eMajor driver: defending against ANDA challenges from generics\u003c\/li\u003e\n\u003cli\u003eImpact: lower operating margin, higher cash burn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupernus pays FDA application fees (PDUFA user fee FY2025: $3.1M for new drug applications) plus state and foreign regulatory charges; facility inspections and annual maintenance add ~$0.5-2.0M\/year depending on product mix.\u003c\/p\u003e\n\u003cp\u003eOngoing pharmacovigilance-safety monitoring, adverse event reporting, risk management-requires dedicated staff and systems, often costing 1-3% of annual sales (e.g., $2-10M for mid-size product lines).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA PDUFA fee FY2025: $3.1M for NDA\u003c\/li\u003e\n\u003cli\u003eInspection\/maintenance: $0.5-2.0M\/year\u003c\/li\u003e\n\u003cli\u003ePharmacovigilance: 1-3% of sales (~$2-10M)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus: R\u0026amp;D‑heavy \u0026amp; SG\u0026amp;A‑laden cost base - IP, PDUFA, PV add material expense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus' cost structure is R\u0026amp;D‑heavy (~20-25% of 2024 revenue, $60-75M on $300M), high SG\u0026amp;A ($178.4M, ~45% of 2024 revenue), COGS driven by APIs\/CMO (25-35% of COGS) and manufacturing\/QA (5-10%), annual IP\/legal ~$18-25M, PDUFA fee $3.1M (FY2025), inspections $0.5-2M, pharmacovigilance 1-3% of sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Amount\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$60-75M (20-25% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$178.4M (45% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\/legal\u003c\/td\u003e\n\u003ctd\u003e$18-25M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDUFA fee\u003c\/td\u003e\n\u003ctd\u003e$3.1M (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacovigilance\u003c\/td\u003e\n\u003ctd\u003e1-3% sales ($2-10M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of ADHD Medications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSales of Qelbree and related ADHD products generate revenue via wholesaler and pharmacy channels; in 2024 Qelbree net product sales were $219.6 million, up ~28% year-over-year as adult prescription share rose to roughly 40%, making this stream a core pillar of Supernus Pharmaceuticals' current results and 2025 guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eParkinson's Disease Product Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial sales of GOCOVRI (amantadine) and APOKYN (apomorphine) supply Supernus with a stable Parkinson's revenue stream-GOCOVRI net product sales were about $187 million in 2024 and APOKYN contributed roughly $45 million-supporting recurring income from the Parkinson's segment. These branded, specialty therapies carry premium pricing tied to demonstrated ON\/OFF and dyskinesia benefits, helping diversify Supernus beyond epilepsy and ADHD.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Epilepsy Medication Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrokendi XR and Oxtellar XR still generate meaningful revenue for Supernus Pharmaceuticals, contributing roughly $85-95 million annually in 2024 despite generic pressure; that cash flow funded R\u0026amp;D and supported 2024 total revenue of about $430 million. Managing the tail-pricing, inventory, and lifecycle tactics-remains central to funding next-wave projects and preserving free cash for pipeline milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus earns high-margin revenue from partners licensing its drug assets or brands for defined territories, collecting upfront fees plus milestone payments tied to clinical and sales targets; for example, Supernus reported $45.8 million in licensing and milestone revenue in 2024, boosting non-recurring income.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront fees + milestone payments\u003c\/li\u003e\n\u003cli\u003eTied to clinical\/commercial triggers\u003c\/li\u003e\n\u003cli\u003eLow incremental cost, high margin\u003c\/li\u003e\n\u003cli\u003e$45.8M licensing\/milestone revenue in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income from Third Parties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoyalty income provides Supernus Pharmaceuticals with passive revenue from third-party sales using its proprietary drug-delivery tech, reflecting IP monetization without sales costs; in 2024 Supernus reported roughly $45-55M in licensing and royalty receipts across partnered products (company disclosures). \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow-cost, high-margin revenue\u003c\/li\u003e\n\u003cli\u003e2024 royalties ~ $45-55M\u003c\/li\u003e\n\u003cli\u003eValidates core delivery IP\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQelbree-fueled 2024: $219.6M sales, Parkinsons + legacy drugs and high-margin licensing lift revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQelbree drove growth with $219.6M net sales in 2024 (~28% YoY, ~40% adult share); Parkinson's brands GOCOVRI ~$187M and APOKYN ~$45M added stable revenue; legacy Trokendi\/Oxtellar XR ~ $85-95M funded R\u0026amp;D; licensing\/milestones $45.8M and royalties ~$45-55M in 2024 bolstered nonrecurring, high‑margin income.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 ($M)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQelbree\u003c\/td\u003e\n\u003ctd\u003e219.6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGOCOVRI\u003c\/td\u003e\n\u003ctd\u003e187\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPOKYN\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrokendi\/Oxtellar\u003c\/td\u003e\n\u003ctd\u003e85-95\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\/milestones\u003c\/td\u003e\n\u003ctd\u003e45.8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e45-55\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347614933323,"sku":"supernus-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/supernus-canvas-business-model.webp?v=1779162391","url":"https:\/\/valuechainanalysis.com\/products\/supernus-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}